Showing results (211-220 of 304) with videos related to
Sort By:
Pageof 31
Cancers|August 28, 2019
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic BiomarkerGiacomo Pelizzari, Debora Basile, Silvia Zago, et al.Future Oncology (London, England)|August 11, 2020
Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancerSilvio Ken Garattini, Marta Bonotto, Luca Porcu, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 20, 2018
Prognostic evaluation in palliative care: final results from a prospective cohort studyPaola Ermacora, Micol Mazzer, Miriam Isola, et al.Frontiers in Oncology|September 26, 2022
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approachAlessandra Fabi, Giuseppe Buono, Emilio Bria, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2010
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancerDavid W Miles, Arlene Chan, Luc Y Dirix, et al.Breast (Edinburgh, Scotland)|June 12, 2026
Strengths and pitfalls of NNT and NNH in early breast cancer escalation trialsRoberto Buonaiuto, Federica Pia Mangiacotti, Fabiola Giudici, et al.Cancers|October 28, 2023
Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue SarcomasAngela Buonadonna, Simona Scalone, Davide Lombardi, et al.Cancers|January 8, 2023
The SAFFO Study: Sex-Related Prognostic Role and Cut-Off Definition of Monocyte-to-Lymphocyte Ratio (MLR) in Metastatic Colorectal CancerCamilla Lisanti, Debora Basile, Silvio Ken Garattini, et al.Current Oncology (Toronto, Ont.)|November 26, 2025
Exceptional Response to Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic Endometrial CancerRiccardo Vida, Michele Bartoletti, Lucia Lerda, et al.Breast (Edinburgh, Scotland)|April 3, 2021
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world studyDebora Basile, Lorenzo Gerratana, Carla Corvaja, et al.Pageof 31